Top

Current Diabetes Reports

Published in:

01-12-2019 | Ramipril | Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

Pharmacologic Randomized Clinical Trials in Prevention of Type 2 Diabetes

Authors: William C. Knowler, Jill P. Crandall

Published in: Current Diabetes Reports | Issue 12/2019

Abstract

Purpose of Review

There have been many randomized clinical trials testing lifestyle and drug interventions to prevent the development of type 2 diabetes in nondiabetic adults at high risk of the disease. We review the major trials using pharmacologic interventions with the primary outcome of preventing diabetes. The trials are grouped according to the main mechanism by which the drugs were thought to have the potential for preventing diabetes.

Recent Findings

Drugs in several different classes have been effective in reducing the incidence of diabetes, but evidence for other long-term benefits, such as avoidance of complications and reducing mortality rates, is very limited.

Summary

Both drugs and lifestyle interventions are effective in preventing and delaying the onset of type 2 diabetes in high-risk adults. The choices of what drugs to use and when during the development of type 2 diabetes to introduce them are not clear.

Knowler WC, Crandall JP, Chiasson J-L, Nathan DM. Prevention of type 2 diabetes. In: CS CCC, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, KMV N, Rewers M, Fradkin JE, editors. Diabetes in America, 3rd ed. Vol NIH Pub No. 17-1468. Bethesda, MD: National Institutes of Health; 2018. p. 38–1. to 38-21.

Knowler WC. Prevention of type 2 diabetes. In: Chapter 16 in Bonora E, De Fronzo R, editors. Diabetes epidemiology, genetics, pathogenesis, prevention, and treatment: Endocrinology springer; 2018. https://doi.org/10.1007/978-3-319-27317-4_16-1.

Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990;13(6):610–30. https://doi.org/10.2337/diacare.13.6.610.CrossRefPubMed

Keen H, Jarrett RJ, McCartney P. The ten-year follow-up of the Bedford survey (1962-1972): glucose tolerance and diabetes. Diabetologia. 1982;22(2):73–8.CrossRefPubMed

Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes. 1980;29(1):41–9. https://doi.org/10.2337/diab.29.1.41.CrossRefPubMed

Knowler WC, Sartor G, Melander A, Schersten B. Glucose tolerance and mortality, including a substudy of tolbutamide treatment. Diabetologia. 1997;40(6):680–6. https://doi.org/10.1007/s001250050734.CrossRefPubMed

NAVIGATOR Study Group, Holman RR, Haffner SM, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16):1463–76. https://doi.org/10.1056/NEJMoa1001122.CrossRef

Jarrett RJ, Keen H, Fuller JH, McCartney M. Worsening to diabetes in men with impaired glucose tolerance (“borderline diabetes”). Diabetologia. 1979;16(1):25–30.CrossRefPubMed

Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. https://doi.org/10.1056/NEJMoa012512.CrossRefPubMed

10.

Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, et al. Prevention of type 2 diabetes with troglitazone in the diabetes prevention program. Diabetes. 2005;54(4):1150–6. https://doi.org/10.2337/diabetes.54.4.1150.CrossRefPubMed

11.

Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 2002;51(9):2796–803. https://doi.org/10.2337/diabetes.51.9.2796.CrossRefPubMed

12.

Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V, et al. The Indian diabetes prevention programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289–97. https://doi.org/10.1007/s00125-005-0097-z.CrossRefPubMed

13.

DREAM Trial Investigators, Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368(9541):1096–105. https://doi.org/10.1016/S0140-6736(06)69420-8.CrossRef

14.

Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet. 2010;376(9735):103–11. https://doi.org/10.1016/S0140-6736(10)60746-5.CrossRefPubMed

15.

DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364(12):1104–15. https://doi.org/10.1056/NEJMoa1010949.CrossRefPubMed

16.

Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med. 2000;160(9):1321–6.CrossRefPubMed

17.

Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–61. https://doi.org/10.2337/diacare.27.1.155.CrossRefPubMed

18.

Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297–308. https://doi.org/10.3945/ajcn.111.024927.CrossRefPubMed

19.

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22. https://doi.org/10.1056/NEJMoa1411892.CrossRefPubMed

20.

le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399–409. https://doi.org/10.1016/S0140-6736(17)30069-7.CrossRefPubMed

21.

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359(9323):2072–7. https://doi.org/10.1016/S0140-6736(02)08905-5.CrossRefPubMed

22.

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4):486–94. https://doi.org/10.1001/jama.290.4.486.CrossRefPubMed

23.

Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K, et al. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009;373(9675):1607–14. https://doi.org/10.1016/S0140-6736(09)60222-1.CrossRefPubMed

24.

• Holman RR, Coleman RL, Chan JCN, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(11):877–86. https://doi.org/10.1016/S2213-8587(17)30309-1. This RCT in an Asian population with IGT showed that acarbose reduced incident diabetes by 18% , but failed to confirm the reduction in cardiovascular risk that had been reported from the earlier STOP-NIDDM trial. CrossRefPubMed

25.

DREAM Trial Investigators, Bosch J, Yusuf S, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355(15):1551–62. https://doi.org/10.1056/NEJMoa065061.CrossRef

26.

NAVIGATOR Study Group, Mc Murray JJ, Holman RR, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16):1477–90. https://doi.org/10.1056/NEJMoa1001121.CrossRef

27.

Lachin JM, Christophi CA, Edelstein SL, Ehrmann DA, Hamman RF, Kahn SE, et al. Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes. 2007;56(4):1153–9. https://doi.org/10.2337/db06-0918.CrossRefPubMed

28.

Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes. 2005;54(8):2404–14. https://doi.org/10.2337/diabetes.54.8.2404.CrossRefPubMed

29.

Ratner RE, Christophi CA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab. 2008;93(12):4774–9. https://doi.org/10.1210/jc.2008-0772.CrossRefPubMedPubMedCentral

30.

Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, et al. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet. 2009;374(9702):1677–86. https://doi.org/10.1016/S0140-6736(09)61457-4.CrossRefPubMedCentral

31.

Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the diabetes prevention program outcomes study. Lancet Diabetes Endocrinol. 2015;3(11):866–75. https://doi.org/10.1016/S2213-8587(15)00291-0.CrossRefPubMedCentral

32.

Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care. 2012;35(4):723–30. https://doi.org/10.2337/dc11-1468.CrossRef

33.

American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S13–28. https://doi.org/10.2337/dc19-S002.CrossRef

34.

Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care. 2010;33(6):1173–5. https://doi.org/10.2337/dc09-1203.CrossRefPubMedPubMedCentral

35.

Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care. 2008;31(1):30–5. https://doi.org/10.2337/dc07-1616.CrossRefPubMed

36.

Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017;5:CD012204.PubMed

37.

Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke. 2004;35(5):1073–8. https://doi.org/10.1161/01.STR.0000125864.01546.f2.CrossRefPubMed

38.

Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA. 2001;286(15):1882–5. https://doi.org/10.1001/jama.286.15.1882.CrossRefPubMed

39.

• Pittas AG, Dawson-Hughes B, Sheehan P, et al. Vitamin D supplementation and prevention of type 2 diabetes. N Engl J Med. 2019;381(6):520–30. https://doi.org/10.1056/NEJMoa1900906. Although many observational studies have demonstated an association between diabetes risk and vitamin D deficiency, this large RCT showed that high dose vitamin D (4000 IU daily) supplementation did not reduce incident diabetes in a cohort with prediabetes. CrossRefPubMedPubMedCentral

40.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57. https://doi.org/10.1056/NEJMoa1812389.CrossRefPubMed

41.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720.CrossRefPubMed

42.

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57. https://doi.org/10.1056/NEJMoa1611925.CrossRefPubMed

43.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. https://doi.org/10.1056/NEJMoa1603827.CrossRefPubMedPubMedCentral

44.

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44. https://doi.org/10.1056/NEJMoa1607141.CrossRefPubMed

45.

Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374(14):1321–31. https://doi.org/10.1056/NEJMoa1506930.CrossRefPubMedPubMedCentral

46.

Spence JD, Viscoli CM, Inzucchi SE, Dearborn-Tomazos J, Ford GA, Gorman M, et al. Pioglitazone therapy in patients with stroke and prediabetes: a post hoc analysis of the IRIS randomized clinical trial. JAMA Neurol. 2019;76(5):526–35. https://doi.org/10.1001/jamaneurol.2019.0079.CrossRefPubMedPubMedCentral

47.

Nathan DM, Bennett PH, Crandall JP, Edelstein SL, Goldberg RB, Kahn SE, et al. White NH; and the DPP research group. Does diabetes prevention translate into reduced long-term vascular complications of diabetes? Diabetologia. 2019;62(8):1319–28. https://doi.org/10.1007/s00125-019-4928-8.CrossRefPubMedPubMedCentral

48.

•• Diabetes Prevention Program Research Group. Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the diabetes prevention program and diabetes prevention program outcomes study. Diabetes Care. 2019;42(4):601–8. https://doi.org/10.2337/dc18-1970. In this long-term follow-up of the Diabetes Prevention Program, participants in the metformin treatment arm had durable reduction in diabetes risk over 15 years. The greatest benefit was observed among individuals with higher baseline fasting glucose or HbA _1c and women with a history of GDM. CrossRefPubMedCentral

49.

Moin T, Li J, Duru OK, Ettner S, Turk N, Keckhafer A, et al. Metformin prescription for insured adults with prediabetes from 2010 to 2012: a retrospective cohort study. Ann Intern Med. 2015;162(8):542–8. https://doi.org/10.7326/M14-1773.CrossRefPubMedPubMedCentral

50.

Ali MK, McKeever Bullard K, Imperatore G, Benoit SR, Rolka DB, Albright AL, et al. Reach and use of diabetes prevention Services in the United States, 2016-2017. JAMA Netw Open. 2019;2(5):e193160. https://doi.org/10.1001/jamanetworkopen.2019.3160.CrossRefPubMedPubMedCentral

51.

American Diabetes Association. 3. Prevention or delay of type 2 diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S29–33. https://doi.org/10.2337/dc19-S003.CrossRef

Title: Pharmacologic Randomized Clinical Trials in Prevention of Type 2 Diabetes
Authors: William C. Knowler
Jill P. Crandall
Publication date: 01-12-2019
Publisher: Springer US
Keywords: Ramipril
Insulins
A-Glucosidase Inhibitor
Metformin
Nateglinide
Acarbose
Diabetes Prevention
Insulins
Type 2 Diabetes
Published in: Current Diabetes Reports / Issue 12/2019
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-019-1268-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 12/2019

Diabetic Gastroparesis and Glycaemic Control

Technological Advancements in the Management of Type 2 Diabetes

What the HLA-I!—Classical and Non-classical HLA Class I and Their Potential Roles in Type 1 Diabetes

Human Endogenous Retroviruses and Type 1 Diabetes

The Effects of Lifestyle and/or Vitamin D Supplementation Interventions on Pregnancy Outcomes: What Have We Learned from the DALI Studies?

Pancreatic Islet Transcriptional Enhancers and Diabetes

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage